GSK (LON:GSK) PT Raised to GBX 1,575 at Barclays

GSK (LON:GSK) had its target price raised by investment analysts at Barclays from GBX 1,450 ($18.15) to GBX 1,575 ($19.71) in a note issued to investors on Monday, FlyOnTheWall reports. Barclays‘s price objective points to a potential upside of 4.43% from the stock’s current price.

A number of other equities analysts have also weighed in on GSK. Shore Capital reissued a “buy” rating on shares of GSK in a research report on Friday, June 16th. Berenberg Bank reissued a “buy” rating and set a GBX 1,730 ($21.65) price target on shares of GSK in a research note on Friday, July 28th. Jefferies Financial Group reaffirmed a “hold” rating and issued a GBX 1,575 ($19.71) price objective on shares of GSK in a research report on Monday, June 26th. Citigroup reiterated a “neutral” rating and set a GBX 1,700 ($21.27) target price on shares of GSK in a research report on Monday, June 26th. Finally, Bank of America cut their target price on GSK from GBX 1,450 ($18.15) to GBX 1,390 ($17.39) in a research report on Monday, July 17th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of GBX 1,572.50 ($19.68).

GSK Price Performance

Shares of GSK stock traded down GBX 1.40 ($0.02) during mid-day trading on Monday, reaching GBX 1,508.20 ($18.87). The stock had a trading volume of 4,613,788 shares, compared to its average volume of 7,055,269. The company has a market cap of £61.84 billion, a P/E ratio of 1,187.56, a price-to-earnings-growth ratio of 0.98 and a beta of 0.30. The company has a current ratio of 0.88, a quick ratio of 0.73 and a debt-to-equity ratio of 176.61. GSK has a 12-month low of GBX 1,280.92 ($16.03) and a 12-month high of GBX 1,609 ($20.14). The business has a 50-day simple moving average of GBX 1,380.09 and a 200 day simple moving average of GBX 1,407.98.

Insiders Place Their Bets

In other news, insider Jonathan Symonds bought 6,000 shares of the business’s stock in a transaction on Friday, June 23rd. The stock was purchased at an average cost of GBX 1,440 ($18.02) per share, for a total transaction of £86,400 ($108,121.64). In other news, insider Jonathan Symonds bought 6,000 shares of the stock in a transaction that occurred on Friday, June 23rd. The shares were purchased at an average cost of GBX 1,440 ($18.02) per share, with a total value of £86,400 ($108,121.64). Also, insider Hal Barron sold 19,446 shares of the business’s stock in a transaction dated Thursday, August 24th. The stock was sold at an average price of GBX 3,462 ($43.32), for a total transaction of £673,220.52 ($842,473.43). In the last three months, insiders have purchased 6,018 shares of company stock worth $8,664,147. 1.74% of the stock is owned by corporate insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.